This excerpt taken from the MDVN 8-K filed Jul 30, 2008.
Dimebon Preserves All Key Functions in Alzheimers Patients for 18 Months in Open-Label Extension of First Pivotal Trial
New data from a six-month open-label extension of the 12-month placebo-controlled study of Dimebon in patients with mild-to-moderate Alzheimers disease demonstrated that Dimebon continued to improve the clinical course of the disease. After 18 months of treatment, Dimebon preserved function in patients at or near their original levels upon entering the trial across all key aspects of Alzheimers disease, specifically memory and thinking, behavior, activities of daily living and overall function. These results are noteworthy as untreated Alzheimers patients progressively deteriorate over time in these areas. Dimebon remained well tolerated throughout the 18-month treatment period.
The open-label extension data were presented in a poster session by Jeffrey Cummings, M.D., Director of the Mary S. Easton Center for Alzheimers Disease Research at UCLA. To my knowledge, no other approved or investigational treatment has stabilized function across all facets of Alzheimers disease for this length of time, said Dr. Cummings. These data suggest that Dimebon may provide long-term benefits to Alzheimers patients and provide further support for its potential as a promising therapeutic to treat this devastating disease.
Patients originally on placebo for 12 months who were then crossed over to Dimebon in the open-label extension phase stabilized across all key measures tested. Since these patients had declined over the previous 12 months while on placebo, they generally stabilized at a lower level of function than those treated with Dimebon for the full 18 months, suggesting a benefit of earlier treatment.